Nature Communications, 2017 A major drawback in the clinical use of the oral anticoagulants that directly inhibit factor Xa in order to prevent blood clot formation is the potential for life threatening bleeding events.
Daniël Verhoef +6 more
doaj +3 more sources
Discovery and development of Factor Xa inhibitors (2015–2022)
Frontiers in Pharmacology, 2023 As a pathological coagulation process, thrombus can lead to many serious diseases, including ischemic stroke, acute myocardial infarction (AMI), acute coronary syndrome (ACS), and deep venous thrombosis (DVT).
Wei Zheng +5 more
doaj +2 more sources
In-house chromogenic anti-factor Xa assay: development, validation, and identification of factors predicting APTT discordance [PDF]
Frontiers in MedicineBackgroundActivated partial thromboplastin time (APTT) is the conventional test for monitoring unfractionated heparin (UFH) therapy, but discordance with anti-factor Xa results frequently occurs in clinical practice, potentially leading to suboptimal ...
Lin Sun +7 more
doaj +2 more sources
Clinical and Applied Thrombosis/Hemostasis, 2019 The currently available oral anti-Xa agents are claimed to produce their anticoagulant and antithrombotic effects solely by the inhibition of factor Xa.
Fakiha Siddiqui BDS +5 more
doaj +2 more sources
Daboxin P, a Major Phospholipase A2 Enzyme from the Indian Daboia russelii russelii Venom Targets Factor X and Factor Xa for Its Anticoagulant Activity. [PDF]
PLoS ONE, 2016 In the present study a major protein has been purified from the venom of Indian Daboia russelii russelii using gel filtration, ion exchange and Rp-HPLC techniques.
Maitreyee Sharma +6 more
doaj +2 more sources
Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors [PDF]
Scientific ReportsDirect oral anticoagulants (DOACs) have been used clinically in patients with chronic thromboembolic pulmonary hypertension (CTEPH) for secondary prevention after acute venous thromboembolism, although the data are limited.
Yoshihisa Nakano +8 more
doaj +2 more sources
AN IN-SILICO STUDY OF SOME NATURAL AND SYNTHETIC COMPOUNDS AS POTENTIAL INHIBITORS FOR FACTOR XA [PDF]
Bulletin of Pharmaceutical Sciences. Assiut University, 2022 Recent research has demonstrated the significance of factor Xa and its inhibitors as a possible treatment approach. Since currently approved drugs have a wide variety of side effects, new anticoagulants must be developed.
Lara AlBeik +2 more
doaj +1 more source
Non-vitamin K oral antagonist failure and tailored treatment in patients with atrial fibrillation and stroke [PDF]
Precision and Future Medicine, 2020 In case of any embolic event, treatment strategy should be established according to the pathomechanisms of failure of non-vitamin K oral anticoagulants (NOAC). A 72-year-old man was referred to our hospital with a sudden speech disturbance.
Hyung Jun Kim +3 more
doaj +1 more source
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors
Circulation, 2023 Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, phase-3b ...
T. Milling +109 more
semanticscholar +1 more source
Direct oral anticoagulant: Review article
Journal of Family Medicine and Primary Care, 2022 Venous thromboembolism (VTE) and atrial fibrillation (AF) is a major burden on the health care system. The average occurrence of venous thromboembolism annually is around 108 per 100,000 person-year.
Abdulrahman Nasiri +5 more
doaj +1 more source